Adamis Pharmaceuticals announces second quarter 2018 financial results
Adamis reported the net loss from operations for the three months ending June 30, 2018 and 2017, respectively, was $9.7 million and $4.9 million. Revenues were $3.9 million and $3.8 million for the three months ended June 30, 2018 and 2017. August 10, 2018